GlobeStar Therapeutics Company Description

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases.

It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021.

GlobeStar Therapeutics Corporation is based in Richland, Washington.

GlobeStar Therapeutics Corporation

Country	United States
Industry	Biotechnology
Sector	Healthcare
CEO	James Katzaroff

Contact Details

Address: 719 Jadewin Avenue Richland, Wyoming 99352 United States
Phone	206 451 1970
Website	globestartherapeutics.com

Stock Details

Ticker Symbol	GSTC
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	October - September
Reporting Currency	USD
ISIN Number	US37960P1049
SIC Code	2836

Key Executives

Name	Position
James C. Katzaroff	President, Chief Executive Officer, Secretary, Principal Executive Officer and Chairman of the Board
Brooke Greenwald	Chief Marketing Officer
David Croom	Executive Vice President